Hansa Biopharma AB (Nasdaq Stockholm: HNSA), a company that deals with enzyme technology for rare immunological conditions, has signed a preclinical research collaboration agreement with Netherlands-based argenx BV, it was reported on 29 March 2021.

This contract has been signed to assess the therapeutic potential of integrating the two firm's IgG (immunoglobulin G) -modulating technologies.

The preclinical research collaboration has been established to explore the potential of integrating imlifidase, Hansa's IgG antibody-cleaving enzyme, and efgartigimod, argenx's FcRn antagonist, which are both in development for indications known to be driven by disease-causing IgGs. A combination of imlifidase and efgartigimod could potentially be utilised in both the acute and chronic setting of autoimmune diseases and transplantation.

Both parties are to contribute equally in terms of resource allocation and will share all intellectual property and data developed through the partnership. The companies will retain exclusive rights to their respective technologies and products.